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PCATHETER AORTIC VALVE IMPLANTATION
Transapical Aortic Valve Implantation
in 175 Consecutive Patients
Excellent Outcome in Very High-Risk Patients
Miralem Pasic, MD, PHD, Axel Unbehaun, MD, Stephan Dreysse, MD, Thorsten Drews, MD,
Semih Buz, MD, Marian Kukucka, MD, Alexander Mladenow, MD, Tom Gromann, MD,
Roland Hetzer, MD, PHD
Berlin, Germany
Objectives The aim of this study was to evaluate the outcome of transapical aortic valve implantation in a single center
with expanded procedural experience and to compare it with predicted risk for conventional aortic valve surgery.
Background Transapical aortic valve implantation is a new approach for high-risk patients with severe aortic stenosis. There
are only limited single-center experiences with very small numbers of patients.
Methods Since April 2008, transapical aortic valve implantation was performed in 175 consecutive patients. The mean
patient age was 79.8  9 years, with a range of 36 to 97 years. The mean Society of Thoracic Surgeons score
was 23.5  19.4% (range 2.7% to 89.5%); 98.3% of patients were in New York Heart Association functional
class III or IV. Ten patients were in cardiogenic shock.
Results Technical success of the procedure was 100%. There was no conversion to conventional surgery. Cardiopulmo-
nary bypass was used in 8 patients (6 elective, 2 emergency). The 30-day mortality was 5.1% for the entire
group, 3.6% for all patients without cardiogenic shock, and 30% for the patients with cardiogenic shock. Survival
at 1, 6, and 12 months was 94.9%, 85.5%, and 82.6%, respectively.
Conclusions The outcome of transapical aortic valve implantation was very favorable and already reproducible during the
learning curve. The method has become de facto our institutional primary choice for treatment of high-risk pa-
tients with severe aortic valve stenosis. (J Am Coll Cardiol 2010;56:813–20) © 2010 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.065p
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sransapical aortic valve implantation is a new therapeutic
pproach in high-risk patients with severe aortic valve
tenosis (1–8). It is necessary for this new procedure to
atch the results of the established method, and then to
xceed them. It should be proved as a safe and reliable
rocedure to be applied in all high-risk patients. Therefore,
he institutional learning curve for the new treatment is a
ery sensitive phase. However, transapical aortic valve im-
lantation departs from standard surgical policies and re-
uires new ways of thinking. The team approach with
ooperation between surgeons, cardiologists, and anesthesi-
logists means that responsibilities in the team must be
efined very precisely and must be well coordinated. It also
eeds a special hybrid operating room that combines a
atheter laboratory with the preconditions necessary to
rom the Deutsches Herzzentrum Berlin, Berlin, Germany. Prof. Pasic and Drs.
nbehaun, Dreysse, Drews, and Buz have been proctors to Edwards Lifesciences
ince July 2009. All other authors report that they have no relationships to disclose.W
Manuscript received January 4, 2010; revised manuscript received February 11,
010, accepted February 15, 2010.erform surgery and sterile valve preparation before implan-
ation, anesthesiologic equipment, appropriate lighting, and
he heart-lung machine. Until optimal organization is
chieved, the results of the new procedure during the
earning curve may be affected negatively by procedural
uestions. We report our initial experience with the first 175
atients during the learning curve for establishing this new
ethod.
ethods
atients. Between April 27, 2008, and October 16, 2009,
ransapical aortic valve implantation was performed in 175
onsecutive high-risk patients with aortic valve stenosis.
atients were considered for the procedure if the Society of
horacic Surgeons (STS) score was 10% or higher. The
nly exclusion criteria were active valve endocarditis or an
ortic annulus diameter of more than 24 mm. Severe
omorbidity was not considered a contraindication. The
tudy was approved by our institutional review committee.ritten informed consent was obtained from all patients or
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Transapical Aortic Valve Implantation August 31, 2010:813–20their representatives. The mean
follow-up was 6 months, with a
range from 1 to 18 months.
Patient baseline characteristics.
The mean age of patients was
79.8  9 years (range 36 to 97
years). The baseline demo-
graphic factors, risk factors, he-
modynamic measurements, and
laboratory values of the patients
are shown in Table 1. There were
120 women and 55 men. The
mean STS score for the entire group
was 23.5  19.4% (range 2.7% to
9.5%). Ten patients had an STS score of 10% but were
onsidered high-risk candidates for conventional surgery
nd also were treated by transapical aortic valve implanta-
ion. The main pathologic features giving rise to this
ecision were severe to complete circular calcification of the
scending aorta (so-called porcelain aorta) in 4 patients,
evere pulmonary hypertension in 2 patients, long-term
mmunosuppressive therapy in 2 patients, lever cirrhosis in
patient, and malignancy in 1 patient. Ten patients were in
ardiogenic shock with a mean STS score of 67.1  29.0%
range 14.7% to 89.5%). Twelve patients had degeneration
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CT  computed
tomography
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
TEE  transesophageal
echocardiography
re-Operative Characteristics in 175 PatientsTable 1 Pre-Operative Characteristics in 175 Patients
Characteristic Value Range %
Age (yrs) 79.8 9.0 36–97 —
Female 120 — 70
Body mass index (kg/m2) 26.6 4.7 17.1–45.0 —
STS score 23.5 19.4 2.7–89.5 —
Logistic EuroSCORE (%) 38.3 19.7 6.3–96.7 —
Mean aortic valve area (cm2) 0.57 0.22 0.22–1.16 —
Mean dP (mm Hg) 46.5 13.9 11.8–97.5 —
Aortic annulus diameter (mm) 22.1 1.3 19–24 —
NYHA functional class III or IV 172 — 98.3
Cardiogenic shock 10 — 5.7
Coronary artery disease 66 — 37.7
Mitral regurgitation grade 3 or 4 12 — 6.8
Tricuspid regurgitation grade 3 or 4 6 — 3.4
Pulmonary hypertension 66 — 37.7
Porcelain aorta 8 — 4.5
Mean LVEF (%) 52 18 10–83 —
LVEF 35% 40 — 22.8
Previous CABG 18 — 10.2
Previous aortic valve replacement 12 — 6.9
Previous mitral valve surgery 4 — 2.3
Atrial fibrillation 65 — 37
Pre-operative IABP 2 — 1.1
Pacemaker 31 — 17.7
Creatinine (mg/dl) 1.3 0.7 0.5–6.3 —
Cancer or other malignancy 10 — 5.7
Liver cirrhosis 4 — 2.3
ABG  coronary artery bypass grafting; dP  mean transvalvular gradient; IABP  intraaorticw
alloon pump; LVEF left ventricular ejection fraction; NYHA New York Heart Association; STS
ociety of Thoracic Surgeons.f previously implanted biologic aortic valve prostheses.
ne hundred seventy-two patients (98.3%) were in New
ork Heart Association functional class III or IV.
re-operative examinations. The pre-operative examina-
ions included clinical and blood examinations, electrocar-
iography, chest X-ray, coronary angiography, transthoracic
chocardiography, cranial computed tomography (CT), CT
f the chest and pelvis, and ultrasound examinations (Dopp-
er) of the arteries and veins of the lower extremities and of
he carotid arteries. Physical examination, neurologic clini-
al findings, transthoracic echocardiography, cranial and
hest CT, and the battery of blood examinations were
epeated during the first week after surgery.
ducation of the team and team building. We educated a
eam consisting of 5 surgeons, 2 cardiologists, and 2
nesthesiologists with expertise in echocardiography dedi-
ated to this program to be able to run it at our institution
4 h/day. The team was trained by theoretical procedural
reparation, followed by training on a computer simulator
nd by dry runs to practice handling the equipment and to
mprove coordination between the members of the team.
art of the training consisted of visits to teaching centers in
eipzig, Germany, and Rouen, France, with procedural
ife-case demonstrations. The first 2 procedures at our
nstitution were proctored by Prof. Thomas Walther from
eipzig, Germany.
urgical technique. Aortic valve implantation was per-
ormed through a mini left anterior thoracotomy (Fig. 1) via
he transapical route with a balloon-expandable transcath-
ter stent-prosthetic xenograft valve (Edwards SAPIEN
HV, Edwards Lifesciences, Irvine, California) of 23 or 26
m diameter. Implantations were performed in our hybrid
perating room (Fig. 2) with a monoplane angiography
ystem by our team of cardiac surgeons, a cardiologist, and
nesthesiologists. A perfusionist and a heart-lung machine
Figure 1 Approach
Excellent access to the apex of the heart through the left mini anterior
thoracotomy. LAD  left anterior descending artery; LV  left ventricular.ere present in the operating room. The procedure was
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August 31, 2010:813–20 Transapical Aortic Valve Implantationivided into a series of sequences performed step by step.
he principal surgical technique, as described in detail by
alther et al. (1), was used in the first 20 patients and later
ith several of our modifications. The most important
odification of the technique was angiographic visualiza-
ion of the aortic root while the prosthetic valve was being
eployed slowly. It enabled easy correction of the position of
he valve with perfect presentation of the relationships
etween the prosthetic valve, aortic valve annulus, aortic
usps, and the coronary arteries (Fig. 3). The procedure was
onitored by fluoroscopy, angiography, and intraoperative
ransesophageal echocardiography (TEE). Our anesthesiol-
gists with expertise in echocardiography performed con-
inuous TEE during the procedure. Transcranial Doppler
ltrasound monitoring for cerebral embolism also was
erformed.
hoice of valve size. The size of the valve used was
etermined according to the diameter of the native aortic
alve annulus measured by intraoperative TEE. We chose a
alve size of 23 mm for aortic valve annuli smaller than 21
m and a 26-mm prosthesis for annulus diameter of 21 mm
r more. Annulus diameter of 24 mm was the upper limit
or the 26-mm valve. The orientation value for the lower
imit for the 23-mm valve was a diameter of the native aortic
nnulus of 19 mm. In borderline cases, the decision was
ade on an individual basis, taking into account additional
actors such as the distances from the annulus to the
oronary artery ostia, the shape of the annulus (oval versus
ircular), the amount of material in the leaflets, aortic
iameters at the level of the sinuses of Valsalva, the
inotubular junction and ascending aorta, and the amount of
alcification in the left ventricular outflow tract, anterior
itral leaflet, and aortic valve leaflets themselves.
nstitutional procedural polices. We have established in-
Figure 2 The Hybrid Operating Room
A special operating room that combines a catheter laboratory with the precon-
ditions necessary to perform surgery and sterile valve preparation before
implantation, anesthesiologic equipment, appropriate lighting, and the heart-
lung machine.titutional policies concerning the procedure that havevolved according to our own experience. These contain our
uidelines on how to act in particular situations with regard
o patient selection, procedural steps, and complications.
he most important 7 principles are:
. “No exclusion” policy: all patients with STS score of 10%
or higher are evaluated as candidates for treatment
regardless of comorbidities and clinical status, for exam-
ple, profound shock (except patients with active endo-
carditis), if it is technically possible to perform the
procedure in terms of the annular size.
. Elective femoro-femoral cardiopulmonary bypass is con-
sidered in patients with severe cardiogenic shock, poor
left ventricular function (left ventricular ejection fraction
[LVEF] 10% to 20%), or both.
. Intra-aortic balloon pump was applied prophylactically
in very high-risk patients (only at the beginning of the
study; later, the decision was based only on the patient’s
hemodynamic condition).
. Concomitant mitral or tricuspid valve pathologic features
are not treated simultaneously, but later on by surgery, if
necessary.
. Simultaneous elective coronary artery stent implantation
is considered in patients with concomitant coronary
artery disease. Only the most relevant coronary artery
stenosis is treated (not applied in the first 25 patients but
introduced later, after post-operative myocardial infarc-
tion occurred in 1 patient).
. Intraoperative valve regurgitation (central, paravalvular,
or both): aortic regurgitation after valve implantation of
grade 1 to 2 should be treated by additional balloon
dilation of the valve and, if necessary, by implantation of
Figure 3 Valve Deployment
Our modification of the procedure performing intraoperative angiography during
slow and gradual valve deployment. If the position is not ideal, it can be corrected
easily by pushing or pulling the catheter with the mounted prosthetic valve.
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Transapical Aortic Valve Implantation August 31, 2010:813–20a second valve. If it is not correctable, conventional
surgical aortic valve replacement should be performed.
. Special situations: Patients with STS score lower than
10% are not considered for transapical valve implanta-
tion, except for clear surgical reasons, for example,
porcelain aorta. Patients with a very high STS score but
with a contraindication for transcatheter procedure (e.g.,
patients with previous mitral valve replacement) may be
evaluated for transapical valve implantation.
tatistical analysis. Continuous variables are expressed as
ean  SD and maximal and minimal absolute numbers.
tatistical analyses were carried out with the Student t test,
he chi-square test, or the Fisher exact test. The paired t test
as used for pre- and post-operative comparisons, and the
npaired t test was used for comparisons between the 23-
nd 26-mm prostheses. Univariate logistic regression was
pplied to identify predictors for post-operative survival.
he data were evaluated by SPSS software version 17.0 for
indows (SPSS, Inc., Chicago, Illinois). A p value 0.05
as considered to be significant.
esults
arly outcome. Technical procedural success was 100%.
here was no conversion to open heart surgery. The 30-day
ortality was 5.1% (9 patients died after surgery) for the
ntire group. It was 8% (n  4) in the first 50 patients, 4%
n 2) in the second 50 patients, and 4% (n 3) in the last
5 patients. In the subgroup of 165 patients without
ardiogenic shock, the 30-day mortality was 3.6% (6 pa-
ients died). Of 10 patients with cardiogenic shock, 3 died
30%). The mean STS score of all patients who died during
he first month was 19.9  10.2% (range 5.8% to 32.4%).
he causes of early deaths were septicemia in 1 patient with
re-operative methycillin-resistant Staphylococcus aureus,
cute myocardial failure in 1 patient, multiorgan failure in 4
atients, basilar vein thrombosis in 1 patient, and abdominal
omplications in 2 patients.
rocedural course. The 26-mm valves were implanted in
07 patients, and 23-mm valves were implanted in 68
atients. During the same procedure, 5 patients received a
econd valve implanted within the first valve (valve in valve)
fter redilation of the first valve because of a paravalvular
eak and relevant regurgitation. The implantation of valves
n patients with degeneration of previously implanted bio-
ogic aortic valve prostheses (valve in an old valve) was
ntirely uneventful in all 12 patients. Concomitantly to
ortic valve implantation, additional elective procedures
ere performed in 29 (16.6%) patients (Table 2). Elective
emoro-femoral cardiopulmonary bypass was applied in 6
3.4%) patients with severe cardiogenic shock, poor left
entricular function (LVEF 10% to 20%), or both. The
ean cardiopulmonary bypass time was 12 min (range 5 to
5 min). An intra-aortic balloon pump was inserted elec-
ively during the procedure in 2 patients with pre-operative
oor LVEF. tntraoperative echocardiographic data. The mean pre-
perative transvalvular gradient was 46.5  13.9 mm Hg
range 11.8 to 97.5 mm Hg), and the mean aortic valve area
as 0.57  0.22 cm2 (range 0.22 to 1.16 cm2). The mean
ost-operative transvalvular gradient was 6.28  2.94 mm
g (range 1.19 to 15.56 mm Hg), and the mean aortic
alve area was 1.88  0.51 cm2 (range 0.85 to 3.37 cm2)
Fig. 4A). According to the size of the implanted valves (23
r 26 mm), the mean transvalvular gradient for the 23-mm
alves was 6.37  2.4 mm Hg (range 1.8 to 11.7 mm Hg),
nd for the 26-mm valves, it was 6.17  3.35 mm Hg
range 1.19 to 15.56 mm Hg) (Fig. 4B). There was no
tatistically significance difference between the transval-
ular gradients in the subgroup of patients with 23-mm
alves and the patients with 26-mm valves (p  0.76)
Fig. 4C). However, there was a significant difference
p  0.001) in the mean aortic area between the 2
ubgroups. The mean aortic valve area of the patients
eceiving 23-mm valves was 1.69  0.49 cm2 (range 0.85
o 2.88 cm2), and in 26-mm valve recipients it was 2.05 
.47 cm2 (range 1.0 to 3.37 cm2) (Fig. 4D).
rocedural and post-operative complications. In 2
1.1%) patients, cardiopulmonary bypass was used on an
mergency basis because of inadequate hemodynamic recov-
ry immediately after valve deployment. In one of them, the
ause was obstruction of the left coronary ostium after
eployment of the valve. Emergency femoro-femoral car-
iopulmonary bypass was established to stabilize the hemo-
ynamic situation during successful implantation of a stent,
nd for additional myocardial reperfusion (total cardiopul-
onary bypass time, 56 min). An intra-aortic balloon pump
lso was implanted. The further post-operative course of the
atient was uneventful. She was weaned from the ventilator
nd the intra-aortic balloon pump was explanted on the first
ost-operative day. In 3 patients, there were intraoperative
roblems with bleeding from the apex of the heart. All
atients with intraoperative hemostatic problems had re-
eived clopidogrel before surgery. There was no aortic
issection, no new or increased mitral valve incompetence,
nd no valve dislocation or dysfunction.
There were 2 cases of post-operative surgical revision
lective Procedures Combinedith Transapical ImplantationTable 2 Elective Procedures CombinedWith Transapical Implantation
Procedure No. of Patients
Coronary artery stenting (elective) 22
ASD II closure with an occlusion device 1
Dilation of the stenotic pulmonary valve 1
LV aneurysmectomy 2
Renal artery stenting 1
Off-pump CABG 1
Permanent caval filter* 1
Closure of a groin arteriovenous fistula* 1
The same patient.
ASD II  secundum atrial septal defect; LV  left ventricle; other abbreviation as in Table 1.hrough the same mini anterior thoracotomy because of
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August 31, 2010:813–20 Transapical Aortic Valve Implantationost-operative bleeding. These patients also had been
reated with clopidogrel before surgery. Ten patients (5.7%)
equired pacemaker implantation because of higher-grade
ortic valve block after surgery. In 1 patient, a 1-cm apical
seudoaneurysm was seen in the post-operative CT. The
pex of the heart was explored on the seventh post-operative
ay, and the pseudoaneurysm was closed uneventfully
hrough the previous mini anterior left thoracotomy and
ithout need for cardiopulmonary bypass. In 1 patient with
oronary artery disease, myocardial infarction occurred on
he first post-operative day. He immediately received an
ntra-aortic balloon pump, and then 3 stents were placed in
he diseased right coronary artery. He recovered well, but
he post-operative course was prolonged. There were 2 cases
f post-operative wound problems: in 1 patient who had
ad methycillin-resistant Staphylococcus aureus before sur-
ery, thoracotomy wound secretion developed. She died
fter surgery of septicemia. Another patient with shock,
nasarca, and severe ascites had an inguinal lymph fistula
ollowed by inguinal wound infection after femoro-femoral
ardiopulmonary bypass. The patient additionally had ileus
Figure 4 Intraoperative Transesophageal Echocardiography Dat
(A to D) Bar graphs showing that transapical aortic valve implantation significantly
pre-operative transvalvular gradient and improved the mean aortic valve area. Preond died of multiorgan failure. Thrombosis of the common eemoral artery at the puncture site occurred in 1 patient with
eripheral arterial disease, and abdominal complications
eeded surgical revision in 3 patients.
One patient experienced a new clinical neurologic deficit
fter surgery. One patient had severe central valvular regur-
itation during the follow-up. She was treated successfully
gain with transapical implantation 10 months after the
rimary procedure. Prosthetic valve endocarditis occurred in
patient after urinary tract infection, 4 months after
ransapical valve implantation. The stent valve was replaced
ith a standard biological valve. After an initial uneventful
ourse, this patient had abdominal complications (gastroin-
estinal bleeding) and died.
ate survival and predictors of survival. The survival at 1,
, and 12 months was 94.9  1.9%, 85.5  3.0%, and
2.6  3.6%, respectively. The mean STS score of all
atients who died during the follow-up was 38.4  27.1%
range 5.1% to 89.5%). Univariate analysis of more than 30
re-operative variables indicated cardiogenic shock, body
ass index, and maximal oxygen uptake as predictors for
ed the mean
efore surgery; Postop.  after surgery.a
reduc
p.  barly death during the first 30 post-operative days (Table 3).
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Transapical Aortic Valve Implantation August 31, 2010:813–20nivariate analyses at 12 months showed 10 independent
redictors for late survival (Table 4).
iscussion
utcome. Our results of transapical valve implantation in
75 high-risk patients proved that this method can achieve
etter results than those of conventional surgery as predicted
y risk factors. The success rate improved with our increas-
ng experience, with the mortality rate falling from 8% in
he first 50 patients to 4% later on. The main consequence
f our favorable results is that transapical valve implantation
as gradually become de facto the primary choice for
reatment of high-risk patients with severe aortic valve
tenosis.
ransapical approach needs longer learning curve. The
mportance of the learning curve was demonstrated clearly
n the published experience (3–8). Procedural success im-
roved from the initial 78% to 96% (5,6), followed by
redictive Factors of 30-Day MortalityTable 3 Predictive Factors of 30-Day Mortality
Parameter
Odds
Ratio
95% Confidence
Interval p Value
Age 1.01 0.93–1.10 0.838
Sex — — —
Body mass index 1.13 1.00–1.26 0.043
Logistic EuroSCORE 1.00 0.97–1.04 0.989
STS score 0.98 0.94–1.03 0.591
NYHA functional class 2.75 0.71–10.65 0.144
Cardiogenic shock 4.46 0.82–24.31 0.044
Pro-BNP 1.00 1.00–1.00 0.517
VO2max 0.45 0.24–0.83 0.011
Previous CABG — — —
Previous AVR — — —
Previous MVR — — —
Pulmonary hypertension 2.33 0.60–9.01 0.221
COPD 1.21 0.31–4.68 0.780
FEV1 0.52 0.09–3.01 0.465
Diabetes mellitus — — —
Renal insufficiency 1.00 0.20–5.00 0.996
Serum creatinine 0.67 0.19–2.41 0.537
Coronary artery disease 0.68 0.18–2.61 0.569
Calcification of ascending aorta 0.22 0.03–1.69 0.221
Ischemic cerebral lesion(s) 1.13 0.29–4.38 0.859
Peripheral arterial disease 0.52 0.13–1.99 0.336
Aortic valve regurgitation 0.70 0.21–2.34 0.559
Mitral valve regurgitation 1.26 0.41–3.87 0.691
Tricuspid valve regurgitation 1.04 0.24–4.45 0.961
LVEF 1.01 0.96–1.07 0.616
LVEDD 0.93 0.84–1.03 0.183
dP max 0.98 0.95–1.02 0.290
dP mean 0.97 0.93–1.02 0.264
AVA 0.67 0.01–38.25 0.844
Annulus size 0.84 0.47–1.50 0.562
VA aortic valve area; AVR aortic valve replacement; BNP brain natriuretic peptide; COPD
hronic obstructive pulmonary disease; dP max/mean  maximum/mean transvalvular gradient;
EV1  forced expiratory volume in 1 s; LVEDD  left ventricular end diastolic diameter; MVR 
itral valve repair/replacement; VO2max  maximal oxygen uptake; other abbreviations as in
able 1.mprovement in the early survival rate (4). In contrast to the Aransfemoral way of implantation (4,7,8), the transapical
pproach needs a longer learning curve because of complex-
ty of the technique, which differs from the standard surgical
rocedure (4). Webb et al. (4) reported better improvement
f the initial results in the transarterial approach (mortality
ate reduction from 12.3% in the initial half to 3.6% in the
econd half of 113 patients) than in the transapical approach
reduction of mortality from 25% to 11.1% in 55 patients).
raining of the team is crucial for excellent initial
esults. We believe that our favorable results already
chieved during the learning curve are mostly the result
f the training of the team to work together before we
tarted the clinical program. Coordination between the
embers of the team (cardiologists, anesthesiologists, sur-
eons) was made uniform and was standardized for the
rocedure, with clearly defined roles for each member.
tandard commands and also standard steps for new,
nexpected situations were established. After rebuilding one
f our operating rooms to produce a new hybrid operating
oom and training the team, we started a program of
ransfemoral, transaxillary, and transapical treatment of
redictive Factors of Cumulative Late MortalityTable 4 Predictive Factors of Cumulative Late Mortality
Parameter
Hazard
Ratio
95% Confidence
Interval p Value
Age 1.03 0.98–1.07 0.270
Sex 1.12 0.56–2.25 0.756
Body mass index 1.03 0.96–1.10 0.389
Logistic EuroSCORE 1.03 1.02–1.05 0.001
STS score 1.02 1.01–1.04 0.008
NYHA functional class 2.11 1.09–4.10 0.027
Cardiogenic shock 5.56 2.52–12.28 0.001
ProBNP 1.00 1.00–1.00 0.001
VO2max 0.81 0.68–0.97 0.022
Previous CABG 1.25 0.55–2.88 0.593
Previous AVR 0.81 0.19–3.39 0.773
Previous MVR 1.02 0.14–7.46 0.987
Pulmonary hypertension 1.44 0.73–2.81 0.291
COPD 0.57 0.27–1.21 0.144
FEV1 0.58 0.25–1.36 0.209
Diabetes mellitus 1.28 0.56–2.95 0.557
Renal insufficiency 1.68 0.80–3.52 0.167
Serum creatinine 1.37 1.03–1.82 0.031
Coronary artery disease 0.70 0.36–1.37 0.294
Calcification of ascending aorta 0.82 0.51–1.34 0.433
Ischemic cerebral lesion(s) 1.74 0.87–3.48 0.121
Peripheral arterial disease 0.71 0.37–1.38 0.312
Aortic valve regurgitation 1.07 0.64–1.80 0.796
Mitral valve regurgitation 1.49 0.92–2.39 0.102
Tricuspid valve regurgitation 1.57 0.98–2.53 0.062
LVEF 0.98 0.96–1.00 0.037
LVEDD 0.99 0.95–1.04 0.741
dP max 0.98 0.97–1.00 0.022
dP mean 0.97 0.95–1.00 0.017
AVA 1.23 0.19–7.93 0.825
Annulus size 0.99 0.75–1.31 0.929bbreviations as in Tables 1 and 3.
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August 31, 2010:813–20 Transapical Aortic Valve Implantationortic valve stenosis in very high-risk patients using different
ypes of systems and valves. After every implantation, we
nalyzed the course of the procedure and complications and
dentified possible weak points of the procedure. This
esulted in compilation of our institutional procedural stan-
ards toward the beginning of the program. Our modifica-
ion of the technique by angiographic monitoring during
low and gradual valve deployment significantly improved
he crucial part of the transapical aortic valve implantation
rocess. Furthermore, we noted early that higher position-
ng of the valve than what we had originally been taught
educed or eliminated paravalvular leaks. Last but not least,
e have excellent conditions to perform this procedure in
ur new hybrid operating room that clearly contributed to
he favorable initial results.
A temptingly easy and straightforward procedure.” It is
ecessary to emphasize that the procedure seems—to an
nexperienced observer—to be a temptingly easy and
traightforward procedure. And it really is one if there are
o complications. However, the procedure poses a high risk
f possible dangerous and life-threatening complications
hat can occur at any moment during the procedure. In
ontrast to a standard surgical procedure, if complications
o occur, they are very difficult to control and it is necessary
o be aware of that fact.
lective use of cardiopulmonary bypass. Cardiopulmo-
ary bypass is very rarely necessary for transcatheter aortic
alve implantation. Its use during the beginning of our
earning curve gave us more safety. Elective cardiopulmo-
ary bypass may be helpful in patients with reduced LVEF
nd additional severe mitral valve regurgitation, with coro-
ary artery disease, with severe pulmonary hypertension
ith an enlarged right ventricle, or in unstable hemody-
amic situations. These patients might have ventricular
brillation during or immediately after cessation of rapid
acing for balloon dilatation of the native valve or valve
eployment. However, the final decision of whether to use
ardiopulmonary bypass was left until intraoperative TEE
as performed.
ombined elective coronary artery stenting and trans-
atheter aortic valve implantation. A significant propor-
ion of patients with severe aortic valve stenosis are older
atients with concomitant coronary artery disease. It is not
lear whether any other treatment than medical for coronary
rtery disease is really necessary after severe aortic valve
tenosis is eliminated by transcatheter aortic valve implan-
ation. Coronary artery disease can be treated by stent
mplantation before or after transcatheter aortic valve im-
lantation. However, percutaneous coronary intervention
ay be technically difficult or impossible later on. The
ossible alternative is to treat both pathologies simulta-
eously. The theoretical advantage of this policy is to
liminate completely the risk of complications because of a
athologic feature left untreated during the waiting time for
he second procedure. Our decision to use this approach was
rompted after one of our patients experienced myocardialnfarction on the first post-operative day. We treat only the
ost significant coronary lesion(s) to keep the procedure as
imple as possible.
isk scores for transcatheter aortic valve implantation.
here is no specific risk score to predict early mortality after
ranscatheter aortic valve implantation. Our multivariate
nalysis demonstrated that neither the STS score nor the
ogistic EuroSCORE were predictors for early death, but
nly for survival later on during the follow-up. Although the
uroSCORE has been used in most publications regard-
ng transcatheter aortic valve implantation, we used the
TS score, which is much more valuable. The logistic
uroSCORE overestimates surgical risk in high-risk pa-
ients. Recent publications suggest an actual mortality of
ne third to one half this estimate in high-risk patients in
igh-volume centers (9,10). The EuroSCORE was devel-
ped from surgical data (that are now too old) almost a
ecade and a half ago, and especially for coronary revascu-
arization procedures, and not specifically for aortic valve
eplacement (11). Therefore, transcatheter aortic valve im-
lantation required development of its own risk score.
tudy limitations. The main limitation is that we have no
ontrol group of patients undergoing conventional aortic
alve replacement. However, the calculated operative risk
or the conventional operation as assessed by the STS score
s a valuable method of evaluating the procedural success.
ecause of a short follow-up, there was a very small number
f patients to analyze the late survival. Further multivariate
nalysis could not be reported because of the low number of
nd points. Therefore, our data show only a trend, and a
tudy with larger patient numbers is required.
onclusions
ransapical aortic valve implantation already has proved its
ualities during the learning curve in our institution. The
perative procedure and the equipment are still being
volved and improved. With increased experience and
implified equipment in the future, it is likely that the
rocedure will become a real alternative to the standard
urgical treatment for all patients with aortic valve stenosis,
nd not only for high-risk patients.
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